David M. Davies - Concepedia

Author

David M. Davies

Also Known As

D DAVIES, D Davies, D M Davies, D. Davies, D.M. Davies, David Davies, David M Davies, David M. Davies, David Marc Davies, David M. Davies

Publications

2.7K

Citations

H-Index

Concepts

All Affiliations

King's College London King's College Hospital NHS Foundation Trust Guy's Hospital Eastbourne District General Hospital Kings Health Partners

About

David M. Davies is an author at King's College London specializing in medicine, cell biology, and immunology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	10	10	1.3K
2	Cell Biology	8	8	1.2K
3	Immunology	8	8	763
4	Cellular Therapies	2	2	240
5	Allergy	1	1	28

David M. Davies

Publications

2.3K

Citations

H-Index

Page 1

	Year	Citations
Dual Targeting of ErbB2 and MUC1 in Breast Cancer Using Chimeric Antigen Receptors Engineered to Provide Complementary Signaling Scott Wilkie, May CI van Schalkwyk, Steve Hobbs, Journal of Clinical Immunology Breast OncologyMedicineDual TargetingImmune Checkpoint InhibitorBreast Cancer	2012	480
Retargeting of Human T Cells to Tumor-Associated MUC1: The Evolution of a Chimeric Antigen Receptor Scott Wilkie, Gianfranco Picco, Julie Foster, The Journal of Immunology	2008	344
Selective Expansion of Chimeric Antigen Receptor-targeted T-cells with Potent Effector Function using Interleukin-4 Scott Wilkie, S. Burbridge, Laura Chiapero-Stanke, Journal of Biological Chemistry ImmunologyIl-4 Receptor AlphaImmunologic MechanismAntigen ProcessingCd4 T Cell Responses	2010	190
CAR T-Cells Targeting the Integrin αvβ6 and Co-Expressing the Chemokine Receptor CXCR2 Demonstrate Enhanced Homing and Efficacy against Several Solid Malignancies Lynsey M. Whilding, Leena Halim, Benjamin Draper, Cancers Several Solid MalignanciesImmunologyImmune RegulationImmunoeditingImmunologic Mechanism	2019	188
Hypoxia-sensing CAR T cells provide safety and efficacy in treating solid tumors Paris Kosti, James W. Opzoomer, Karen I. Larios-Martinez, Cell Reports Medicine	2021	131
Preclinical In Vivo Modeling of Cytokine Release Syndrome Induced by ErbB-Retargeted Human T Cells: Identifying a Window of Therapeutic Opportunity? Sjoukje J. C. van der Stegen, David M. Davies, Scott Wilkie, The Journal of Immunology Cell TherapyTherapeutic OpportunityAdaptive Immune SystemT-regulatory CellImmunology	2013	128
Trafficking of CAR-Engineered Human T Cells Following Regional or Systemic Adoptive Transfer in SCID Beige Mice Ana C. Parente‐Pereira, Jerome Burnet, David H. Ellison, Journal of Clinical Immunology Knockout MouseCell TherapyXenotransplantationT-regulatory CellImmunology	2011	112
Flexible Targeting of ErbB Dimers That Drive Tumorigenesis by Using Genetically Engineered T Cells David M. Davies, Julie Foster, Sjoukje J. C. van der Stegen, Molecular Medicine	2012	111
Targeting of Aberrant αvβ6 Integrin Expression in Solid Tumors Using Chimeric Antigen Receptor-Engineered T Cells Lynsey M. Whilding, Ana C. Parente‐Pereira, Tomasz Zabinski, Molecular Therapy	2017	75
CAR T-cell immunotherapy of MET-expressing malignant mesothelioma Thivyan Thayaparan, Roseanna M. Petrovic, Daniela Achkova, OncoImmunology	2017	74

Page 1